News
Zacks.com on MSN10h
Here's What to Expect From Pfizer's Non-Oncology Drugs in Q2 EarningsPFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback